



HHS Public Access

Author manuscript

Ann Allergy Asthma Immunol. Author manuscript; available in PMC 2017 March 01.

Published in final edited form as:

Ann Allergy Asthma Immunol. 2016 March ; 116(3): 179–182. doi:10.1016/j.anai.2016.01.003.

The discovery of IgE 50 years on

Thomas A.E. Platts-Mills, M.D., Ph.D., FRS¹, Peter W. Heymann, M.D.¹, Scott Commins, M.D., PhD^{1,2}, and Judith A. Woodfolk, M.D., PhD

¹Asthma and Allergic Disease Center, University of Virginia

²The University of North Carolina at Chapel Hill

Keywords

Prausnitz-Küstner; IgE; myeloma ND; recognition of IgE

Introduction

In 1906, Von Pirquet used the term “supersensitivity without immunity” to describe; (i) the symptoms of inhalant allergy, (ii) the positive immediate skin tests and (iii) the fact that other tests of immunity were not positive in these patients ¹. The other tests he referred to were precipitin tests and complement fixation. Thus he opened up the question of serum tests for “supersensitivity”. In 1919, Ramirez reported that a patient, who had received a blood transfusion from a horse allergic donor, became allergic to horse dander ². At this point, Prausnitz set out to investigate whether the serum of allergic subjects contained a factor or factors that could sensitize the skin. In 1921, he reported that the local injection of serum from a fish allergic subject, Kuestner, to an individual who was only allergic to pollen, Prausnitz, would transfer specific sensitivity ³. This transfer of sensitivity came to be known as the P-K test and was used widely to study sensitivity not only to common allergens but also to extracts as diverse as those obtained from Schistosomes ^{4, 5}.

Furthermore, Cooke and his colleagues in New York identified that there were other antibodies in the serum that increased during desensitization treatment and could block the skin sensitizing activity ⁶. By the 1950's, it was clear that the transferred sensitivity was specific, that it could be diluted extensively and that the skin remained locally sensitive for days if not weeks after the injection of serum ^{7, 8}. It was also already clear that the ability to sensitize the skin was lost after moderate heating of the serum ⁷. Several studies had also been reported on the physical properties of P-K activity. Indeed Dan Campbell and his

Please send Correspondence to: Thomas A.E. Platts-Mills, MD, PhD, FRS, University of Virginia Health Systems, Asthma and Allergic Disease Center, PO Box 801355, Charlottesville, VA 22980-1355 USA, Tel: (434) 924-5917, Fax: (434) 924-5779, tap2z@virginia.edu.

Trial Registration: Not applicable

Conflicts of Interest: none

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

colleagues at Cal Tech reported on the sedimentation properties of skin sensitizing antibodies in 1960⁹. However, the studies prior to 1964 had not succeeded in defining the nature of these antibodies.

The Purification of P-K activity and evidence that it represented a new isotype of immunoglobulin

Around 1960, Kimishige Ishizaka set out to purify P-K activity from the serum of patients who were allergic to pollen. At that time, seasonal hay fever was much the most common form of allergic disease and these were the sera that had the highest titers of P-K activity. In 1964, his group reported that P-K activity was present in a serum fraction that contained molecules larger than IgG and that included monomeric IgA¹⁰. Those experiments actually suggested that P-K activity might be a property of IgA. However, he went on to disprove that idea based on two observations. Firstly partially purified human IgA antibodies to group A blood substance did not have P-K activity and secondly the P-K activity separated with molecules slightly larger than IgA¹¹. The separation of P-K activity from serum IgA was dependent on using two 100 cm upward flowing, gravity fed, size exclusion columns in series and also on the development by Pharmacia of the cross linked dextran Sephadex G200 as a molecular sieve. This column produced a P-K rich fraction which was further depleted of other immunoglobulins and used to immunize rabbits. Thus by 1966, an antiserum specific for P-K activity had been produced that could deplete the P-K activity from serum, as well as give a precipitin line in a gel¹². They provided evidence at that time that this activity could not be ascribed to IgM, IgG, IgA or IgD antibodies and suggested that it should be regarded as a new isotype which they named gamma E^{13, 14}.

Demonstration that a myeloma derived protein ND was not IgM, IgG, IgA or IgD and could block sensitization of the skin

Meanwhile “back in Europe” the immunochemists Hans Bennich and Gunnar Johansson had become very interested in the nature of the immunoglobulin present in the serum of a patient (ND) who required regular plasmapheresis for multiple myeloma. From a large bank of myeloma sera this was the only one that could not be typed i.e. it was not IgM, IgG, IgA, or the newly defined IgD. The serum from this patient provided an ideal source to study since it contained 10 mg/ml of the myeloma protein. However, it is important to remember that myeloma proteins do not have known antigen specificity which made it difficult to investigate the biological activity. Nonetheless, in 1967 working with Dennis Stanworth and John Humphrey in the UK they digested the molecule with Papain and reported that the Fc fragment of the ND protein could inhibit PK activity¹⁵⁻¹⁷. One of the most remarkable things about the whole story is that the Radio-Allergo Sorbent test (RAST) for IgE antibodies was also published in 1967¹⁸. That paper by Wide, Bennich and Johansson reported assays of IgE to more than twenty different allergens and a significant correlation between the assay results and the results of challenge tests. The availability of myeloma protein, ND, was invaluable in the development of assays of total IgE and IgE antibodies in serum, because there was sufficient fully purified protein not only for the digestion with Papain but also for radiolabeling and production of specific anti-IgE. The protein also made

it possible to carry out a detailed structural analysis of the molecule which was found to have an extra domain in the heavy chain thereby explaining its molecular weight of close to 190,000. In that same year, the two groups exchanged reagents and it became clear that Ishizaka's purified P-K activity and the ND protein purified by Johansson and Bennich carried the same isotype specific determinants. By 1968, the two groups together had enough information to present their results to WHO ¹⁹, and the new isotype was officially named IgE.

Studies on the function and biology of IgE at Johns Hopkins

The importance of the discovery of IgE to our understanding of allergic disease really became obvious from the research that came from each of the groups over the next few years. In 1969, Dr. Ishizaka's group moved from the Children's Asthma Research Institute (CARI) in Denver to Johns Hopkins in Baltimore. There they pursued both the mechanisms of sensitization and release of histamine and also the biology of IgE antibody responses. The work on the role of IgE antibodies addressed the nature of the cells both in the skin and the circulation that bound IgE and contained histamine as well as the role of IgE in triggering these cells ²⁰. Those experiments with Tarruko Ishizaka and Hisaio Tomioka included, identifying the IgE receptor, demonstrating that the same receptor was present on basophils and mast cells and proving that histamine release from basophils required physical cross linking of two IgE receptor molecules ²¹.

The early evidence showing that P-K activity remained stable on the skin for many days implied that the receptor on the cells containing histamine must have a high affinity for IgE. After the discovery of IgE, this was confirmed and indeed it was suggested that the binding was not reversible. However, in 1973, it became clear that IgE could be stripped off histamine containing cells by low pH both in the mouse and in humans ^{22, 23}. Following directly on the early evidence about the Fc Receptor, there have been multiple investigations of the mechanism of histamine release and also on the structure of the IgE receptor focused on explaining its high affinity. The studies on the receptor have had a checkered history with arguments made for a role of many different parts of the IgE molecule ²³ This included progressively refined studies by Jean Pierre Kinet and Henry Metzger. However, the full crystal structure of the receptor obtained by Brian Sutton, Hannah Gould, and their colleagues has now allowed a convincing model of the way in which IgE binds to the receptor ²⁴.

Shortly after the registration of IgE, a second patient producing high levels of IgE was identified in New England, who also required repeated plasmapheresis to prevent excess viscosity. This made it possible to develop high affinity antibodies to IgE that were used to study IgE on basophils and also to develop binding assays to measure IgE antibodies ^{25, 26}. In Baltimore, Kishimoto and Ishizaka initiated studies to understand the mechanisms of IgE production using a rabbit model ²⁷. Those studies provided good evidence that the IgE responses were T cell dependent. In addition, they showed that Complete Freund's Adjuvant (CFA) could switch off IgE production even in rabbit strains that produced excellent IgE responses to the same allergen using alum ²⁸. However, it rapidly became obvious that these experiments would be easier in inbred strains of mice. Indeed, mice have provided an

excellent model for studying the cellular basis of IgE production. In many senses the full understanding of TH1 and TH2 came from studies involving IgE production^{29, 30}. Equally much of the understanding of the relevance of IL-4 and IL-13 came from studies on IgE production³¹⁻³³.

Sensitive and specific assays for IgE and IgE antibodies

After their initial work, Johansson and his colleagues focused on developing the assays for IgE and making them widely available³⁴. This included both assays for specific IgE antibodies and also those for the total quantity of IgE in the circulation. The techniques for measuring total IgE ranged from inhibition radioimmuno assay (RIA) to different forms of assays using anti-IgE on the solid phase. Starting with different particles or paper discs, these assays became progressively more accurate and technically more reliable. The assays for total IgE are standardized relative to an IUIS international standard, and although the values are generally given in international units (IU) it is widely recognized that this unit is equal to 2.4 ng^{35, 36}. Thus it became clear that a serum with 400 IU of IgE/ml contained 1 microgram of IgE/ml which is one ten thousandth of the average quantity of IgG. Although the units of IgE antibodies are often given in Allergy units/ml [or kilo AU/liter] there is good evidence that these IgE antibody units are quantitatively the same as the IU for IgE. This made it possible to estimate the percentage of total IgE that was explained by specific IgE. The initial observations of this kind were made by Gleich and Jacob on IgE to ragweed, but the same is true for grass pollen and dust mite^{36, 37}. Most recently following IgE antibody responses to galactose alpha-1, 3-galactose after tick bites it is clear that this IgE response can be greater than 30% of the total IgE and that the specific IgE ab response can be an important contributor to elevated total IgE^{38, 39}. It is important to recognize that this is the only isotype of immunoglobulin in the human where specific antibodies to one antigen are known to make an important contribution to the total.

Since it was known that anti-IgE could cross link molecules on the surface of basophils or mast cells and trigger histamine release there were obvious objections to using a polyclonal anti-IgE to treat allergic disease. However, once the full structures of circulating IgE and membrane IgE were known it became clear that there were two possible sites on the molecule that could be targeted. The first was the FC binding site that would be shielded as soon as the molecule was bound to Fc epsilon R1 and the second was a small section of the membrane bound IgE that is close to the B cell membrane. It took over twenty years from the first studies on monoclonal antibodies against the Fc binding site to achieve successful treatment of allergic asthma with omalizumab^{40, 41}.

Once the assays for IgE antibodies were possible, they became a normal part of epidemiologic studies as well as clinical practice⁴². When it became obvious that pediatric asthma had dramatically increased between 1960 and the 1980's these assays played a central role both in defining new allergens and in investigating the role of indoor allergens in asthma^{37, 42-45}. From early on it was clear that IgE could be measured using either allergen extracts or purified proteins. However, it was not until the advent of recombinant proteins that widespread use of component assays became possible. With the dramatic rise in food allergy, IgE assays have played a central role both in the investigation and the management.

This is particularly true for conditions such as peanut allergy and delayed anaphylaxis to red meat where the titer of IgE antibodies to Ara h 2 and Alpha-gal, respectively, has a direct relationship to the disease^{39, 46–48}. However in Eosinophilic esophagitis (EoE) where the titers of IgE ab to milk are low or very low, IgE ab to milk components may nonetheless be relevant to designing management^{49, 50}.

Conclusions

There have been several previous reviews of the discovery of IgE with strikingly different emphasis^{14, 17, 34}. Looking back we have to conclude that the joint success of two different research approaches was remarkably good luck for those of us who care about allergic disease. Just at the moment when Ishizaka's group had developed a rabbit antibody specific for the human antibodies that were responsible for P-K activity, Johansson and Bennich had identified a myeloma protein that appeared to be a novel isotype. In addition, they demonstrated that the Fc fragment of that protein would inhibit P-K activity. Once the two groups had collaborated to establish the identity of the new isotype, each group pursued their own research. What followed was a truly dramatic increase in research on allergic disease, ranging from mechanisms of histamine release, to cellular studies on the biology of IgE production, and the development of sensitive and accurate assays of IgE that became available worldwide. Thus the discovery of IgE spawned thousands of studies on the science of IgE as well as on the relevance of IgE antibodies to allergic disease. There have been few discoveries in the last 50 years that have directly resulted in such impressive progress in both the science and the clinical understanding of a major group of diseases.

Acknowledgments

Funding Source: NIH AI-20565

References

1. Von Pirquet, C. Clinical Aspects of Immunology. Gell, PGH., et al., editors. Blackwell Scientific Publications; Oxford: 1906.
2. Ramirez M. Horse asthma following blood transfusion: Report of a case. J Am Med Assoc. 1919; 73:984.
3. Prausnitz C, Kustner H. Studien uber die ueberempfindlichkeit. Zentralbl Bakteriol [Orig A]. 1921; 86:160.
4. Sehon A, Harter J, Rose B. The localization of skin-sensitizing antibody in the sera of ragweed - sensitive individuals by electrophoresis. J Exp Med. 1956; 103:679–99. [PubMed: 13319586]
5. Taliafero WH, Taliafero LG. Skin reaction in persons infected with Schistosoma Mansoni. Puerto Rico J Publ Health trop. 1931; 7:23. Med.
6. Cooke RA, Barnard JH, Hebal S, Stull A. Serological Evidence of Immunity with Coexisting Sensitization in a Type of Human Allergy (Hay Fever). J Exp Med. 1935; 62:733–50. [PubMed: 19870445]
7. Loveless M. Immunological studies of pollinosis: II Passive sensitization of man through transfusion. J Immun. 1941; 41:15.
8. Cass RM, Andersen BR. The disappearance rate of skin-sensitizing antibody activity after intradermal administration. J Allergy. 1968; 42:29–35. [PubMed: 5243796]
9. Heimlich E, Vannier W, Campbell D. Sedimentation studies of skin-sensitizing antibody. J Allergy. 1960; 31:364–9. [PubMed: 14400680]

10. Ishizaka K, Ishizaka T, Hathorn E. Blocking of Prausnitz-Kuestner sensitization with reagin by 'A chain' of human gamma 1A-globulin. *Immunochemistry*. 1964;197–207. [PubMed: 14252227]
11. Ishizaka K, Ishizaka T, Lee E, Fudenberg H. Immunochemical properties of human gamma-A isohemagglutinin. I Comparisons with gamma-G and gamma-M-globulin antibodies. *J Immunol*. 1965; 95:197–208. [PubMed: 4158326]
12. Ishizaka K, Ishizaka T, Hornbrook M. Physico-chemical properties of human reaginic antibody. IV Presence of a unique immunoglobulin as a carrier of reaginic activity. *J Immunol*. 1966; 97:75–85. [PubMed: 4162440]
13. Ishizaka K, Ishizaka T, Hornbrook M. Physicochemical properties of reaginic antibody. V Correlation of reaginic activity with gamma-E-globulin antibody. *J Immunol*. 1966; 97:840–53. [PubMed: 4163008]
14. Ishizaka K, Ishizaka T. Studies on immunoglobulin IgE: The impact of a sojourn with professor Dan H. Campbell at Cal-Tech Immunochemistry. 1975; 12:527–34.
15. Stanworth D, Humphrey J, Bennich H, Johansson S. Specific inhibition of the Prausnitz-Kustner reaction by an atypical human myeloma protein. *Lancet Infect Dis*. 1967; 2:330–2.
16. Stanworth D, Humphrey J, Bennich H, Johansson S. Inhibition of Prausnitz - Kustner reaction by proteolytic - cleavage fragments of a human myeloma protein of Class E. *Lancet*. 1968; ii:17–8.
17. Stanworth D. The discovery of IgE. *Allergy*. 1993; 48:67–71. [PubMed: 8457034]
18. Wide L, Bennich H, Johansson S. Diagnosis of allergy by an in-vitro test for allergen antibodies. *Lancet*. 1967; 2:1105–7. [PubMed: 4168552]
19. Bennich H, Ishizaka K, Johansson S, Rowe D, Stanworth D, Terry W. Immunoglobulin E: a new class of human immunoglobulin. *Immunology*. 1968; 15:323–4. [PubMed: 4176102]
20. Lichtenstein L, Levy D, Ishizaka K. In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release. *Immunology*. 1970; 19:831–42. [PubMed: 4099007]
21. Ishizaka T, Tomioka H, Ishizaka K. Degranulation of human basophil leukocytes by anti-gamma E antibody. *J Immunol*. 1971; 106:705–10. [PubMed: 4100689]
22. Ishizaka T, Ishizaka K. Mechanisms of passive sensitization. IV Dissociation of IgE molecules from basophil receptors at acid pH. *J Immunol*. 1974; 112:1078–84. [PubMed: 4130108]
23. Blank U, Ra C, Miller L, White K, Metzger H, Kinet J. Complete structure and expression in transfected cells of high affinity IgE receptor. *Nature*. 1989; 12:187–9.
24. Sutton BJ, Davies A. Structure and dynamics of IgE-receptor interactions: FcERI and CD23/ FcERII. *Immunol Rev*. 2015; 268:222–35. [PubMed: 26497523]
25. Ishizaka T, De Bernardo R, Tomioka H, Lichtenstein L, Ishizaka K. Identification of basophil granulocytes as a site of allergic histamine release. *J Immunol*. 1972; 108:1000–8. [PubMed: 4112412]
26. Platts-Mills TA, Snajdr MJ, Ishizaka K, Frankland AW. Measurement of IgE antibody by an antigen-binding assay: correlation with PK activity and IgG and IgA antibodies to allergens. *J Immunol*. 1978; 120:1201–10. [PubMed: 641345]
27. Kishimoto T, Ishizaka K. Regulation of antibody response in vitro. V Effect of carrier-specific Helper cells on generation of hapten-specific memory cells of different immunoglobulin classes. *J Immunol*. 1973; 111:1–9. [PubMed: 4541323]
28. Ishizaka K, Kishimoto T. Regulation of antibody response in vitro. II Formation of rabbit reaginic antibody. *J Immunol*. 1972; 109:65–73. [PubMed: 5035246]
29. Mosmann T, Cherwinski H, Bond M, Giedlin M, Coffman R. Two types of murine helper T cell clone. I Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol*. 1986; 136:2348–57. [PubMed: 2419430]
30. Pau W. History of interleukin-4. *Cytokine*. 2015; 75:3–7. [PubMed: 25814340]
31. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. *Science*. 1998; 18:2258–61.
32. Gour N, Wills-Karp M. IL-4 and IL-13 signalling in allergic airway disease. *Cytokine*. 2015; 75:68–78. [PubMed: 26070934]
33. Katona I, Urban JJ, Kang S, Paul W, Finkelman F. IL-4 requirements for the generation of secondary in vivo IgE responses. *J Immunol*. 1991; 146:4215–21. [PubMed: 1674956]

34. Johansson S. The discovery of IgE and its role in Allergy. *Chem Immunol Allergy*. 2014; 100:150–4. [PubMed: 24925395]
35. Hamilton R, Adkinson N. In vitro assays for the diagnosis of IgE-mediated disorders. *J Allergy Clin Immunol*. 2004; 114:213–25. [PubMed: 15316492]
36. Gleich GJ, Jacob GL. Immunoglobulin E antibodies to pollen allergens account for high percentages of total immunoglobulin E protein. *Science*. 1975; 190:1106–8. [PubMed: 1188389]
37. Chapman MD, Platts-Mills TA. Purification and characterization of the major allergen from *Dermatophagoides pteronyssinus*-antigen P1. *J Immunol*. 1980; 125:587–92. [PubMed: 6771329]
38. Chung CH, Mirakhor B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. *N Engl J Med*. 2008; 358:1109–17. [PubMed: 18337601]
39. Commins SP, Kelly LA, Ronmark E, et al. Galactose-alpha-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma. *Am J Respir Crit Care Med*. 2012; 185:723–30. [PubMed: 22281828]
40. Holgate S, Chuchalin A, Hebert J, et al. Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy*. 2004; 34:632–8. [PubMed: 15080818]
41. MacGlashan DJ, Bochner B, Adelman DJ, et al. Down-regulation of Fc (epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol*. 1997; 158:1438–45. [PubMed: 9013989]
42. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. *N Engl J Med*. 1990; 323:502–7. [PubMed: 2377175]
43. Perzanowski MS, Ronmark E, Platts-Mills TA, Lundback B. Effect of cat and dog ownership on sensitization and development of asthma among preteenage children. *Am J Respir Crit Care Med*. 2002; 166:696–702. [PubMed: 12204868]
44. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. *Lancet*. 2001; 357:752–6. [PubMed: 11253969]
45. Custovic A, Soderstrom L, Ahlstedt S, Sly P, Simpson A, Holt P. Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood. *J Allergy Clin Immunol*. 2011; 127:1480–5. [PubMed: 21492924]
46. Flinterman A, Knol E, Lencer D, et al. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. *J Allergy Clin Immunol*. 2008; 121:737–43. [PubMed: 18234310]
47. Du Toit G, Roberts G, Sayre P, Bahnson H, Radulovic S, Santos A. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med*. 2015; 372:803–13. [PubMed: 25705822]
48. Tripathi A, Commins SP, Heymann P, Platts-Mills TA. Delayed anaphylaxis to red meat masquerading as idiopathic anaphylaxis. *JACI in Practice*. 2014 May-Jun;:259–65.
49. Erwin EA, James HR, Gutekunst HM, Russo JM, Kelleher KJ, Platts-Mills TA. Serum IgE measurement and detection of food allergy in pediatric patients with eosinophilic esophagitis. *Ann Allergy Asthma Immunol*. 2010; 104:496–502. [PubMed: 20568382]
50. Erwin E, Tripathi A, Ogbogu P, et al. IgE Antibody Detection and Component Analysis in Patients with Eosinophilic Esophagitis. *J Allergy Clin Immunol Pract*. 2015; 15:00260–3.